Cara Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 06 2021 - 6:00AM
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company
focused on developing and commercializing new chemical entities
designed to alleviate pruritus by selectively targeting peripheral
kappa opioid receptors, or KORs, today announced that Derek
Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will
present at the 39th Annual J.P. Morgan Healthcare Conference on
Wednesday, January 13, 2021 at 2:00 p.m. ET.
A live webcast of the presentation can be
accessed under "Events & Presentations" in the News &
Investors section of the Company's website
at www.CaraTherapeutics.com. An archived webcast recording
will be available on the Cara website for approximately 30
days.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pruritus by selectively
targeting peripheral kappa opioid receptors, or KORs. Cara is
developing a novel and proprietary class of product candidates, led
by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist
that targets the body’s peripheral nervous system, as well as
certain immune cells. The Company has submitted a New Drug
Application (NDA) to the U.S. Food and Drug Administration (FDA)
for KORSUVA™ Injection (difelikefalin) for the treatment of
moderate-to-severe pruritus in hemodialysis patients. KORSUVA
Injection received Breakthrough Therapy Designation from the FDA
for this indication. Cara has requested Priority Review for the NDA
which, if granted, could result in a six-month review process. Oral
KORSUVA has successfully completed a Phase 2 trial for the
treatment of pruritus in patients with CKD and is currently in
Phase 2 trials in atopic dermatitis and primary biliary cholangitis
patients with moderate-to-severe pruritus.
The FDA has conditionally accepted KORSUVA™ as
the trade name for difelikefalin injection. CR845/difelikefalin is
an investigational drug product and its safety and efficacy have
not been fully evaluated by any regulatory authority.
Forward-looking Statements
Statements contained in this press release
regarding matters that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Examples of these
forward-looking statements include statements concerning the
potential regulatory approval of KORSUVA Injection, the potential
for the receipt of Priority Review from the FDA, and the potential
timeline for FDA review of the NDA. Because such statements are
subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Risks are described more fully in Cara's filings with
the Securities and Exchange Commission, including the "Risk
Factors" section of Cara's Quarterly Report on Form 10-Q for the
quarter ended September 30, 2020 and its other documents
subsequently filed with or furnished to the Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. Except to the extent required by law, Cara undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
MEDIA CONTACT: Annie Starr6 Degrees973-768-2170
astarr@6degreespr.com
INVESTOR CONTACT:Janhavi MohiteStern Investor
Relations, Inc.janhavi.mohite@SternIR.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Jul 2023 to Jul 2024